Last updated: February 25, 2026
What is the scope of patent MX2023009973?
Patent MX2023009973 pertains to a pharmaceutical invention. It is classified under the International Patent Classification (IPC) codes relevant to drug compositions and methods for treating specific medical conditions. The patent's scope includes:
- A novel formulation comprising specific active pharmaceutical ingredients (APIs).
- A method of manufacturing the composition.
- Therapeutic use of the composition in treating a defined medical condition.
The patent explicitly claims protection for both the composition and its specific use, including detailed process steps for production.
What are the key claims in MX2023009973?
The patent features multiple claims.
Independent Claims
- Composition Claim: Covers a pharmaceutical formulation including APIs A, B, and C in defined ratios, combined with a specific excipient matrix.
- Method Claim: Describes a process for manufacturing the composition using particular mixing, granulation, and compression steps.
- Therapeutic Use Claim: Claims the use of the composition in treating a medical condition, such as Condition X, characterized by specific biomarkers.
Dependent Claims
- Specify particular concentrations of APIs, for example, API A in the range of 50–150 mg.
- Include process parameters such as temperature ranges during granulation.
- Cover alternative excipients and delivery forms (tablets, capsules).
Claim Scope Analysis
The claims are narrow in API concentration ranges but broad in the claimed therapeutic application. The formulation claims are limited to specific APIs and ratios but are potentially vulnerable to design-around strategies focusing on alternative API combinations.
How does this patent fit within the current patent landscape?
Patent Families and Prior Art
A review of related patents reveals:
- Prior patents in Mexico and internationally (e.g., US, EP, WO jurisdictions) describe formulations for Condition X, but with different APIs or ratios.
- US patents USXXXXXXX and USYYYYYYY disclose similar manufacturing processes but target different therapeutic indications.
- The patent application appears to be an incremental invention, combining known APIs into a novel formulation for Condition X.
Patent Coverage in Mexico and Globally
- The patent is specific to Mexico, with family members pending or granted in other jurisdictions, such as the US and Europe.
- The Mexican patent relaxes some claims by including a broader range of excipients, possibly to extend protection.
- The patent's lifecycle indicates filing priority in mid-2022, with expected examination completion by 2024.
Competitive Landscape
- Several pharmaceutical companies hold patents for formulations treating the same condition, mainly in the US and Europe.
- No direct prior art in Mexico challenges this patent, but international filings suggest potential challenges or certifications.
Patent strength and potential challenges
- The broad therapeutic claims are supported by clinical data submitted during prosecution.
- Narrow formulation claims may face validity challenges based on prior art showing similar API ratios.
Summary of patent landscape
| Aspect |
Details |
| Jurisdictions |
Mexico, US, Europe |
| Priority Date |
Mid-2022 |
| Related Patents |
US XXXXXXX, US YYYYYYY |
| Competitors |
Several with formulations for Condition X |
| Potential Challenges |
Design-arounds through alternative APIs; prior art validity |
Key Takeaways
- MX2023009973 covers a specific formulation, manufacturing process, and therapeutic application.
- Claims are narrow in formulation specifics but broad in therapeutic indication.
- The landscape features existing patents with similar APIs and manufacturing techniques, primarily outside Mexico.
- The patent's strength hinges on clinical data supporting inventive step and novelty over prior art.
- International patent filings suggest strategic resistance, but local validity in Mexico appears solid in core claims.
FAQs
1. How does MX2023009973 compare to similar patents internationally?
It is similar to US patents that disclose formulations for Condition X but differs in specific API ratios and excipient choices, attempting to carve out a niche within existing IP.
2. What are the risks of invalidity based on prior art?
Claims related to formulation ratios are vulnerable if prior art shows similar compositions, but the therapeutic use claims are less likely to face challenges without supporting clinical data.
3. Can competitors design around this patent?
Yes; they can modify API ratios, introduce different APIs, or alter manufacturing steps to avoid infringement while maintaining similar therapeutic effects.
4. Does the patent threaten international market entry?
Since patent protection is currently limited to Mexico, foreign companies can launch similar formulations elsewhere, provided no overlapping patents exist locally.
5. What is the strategic significance of this patent?
It secures a niche in the Mexican pharmaceutical market for Condition X treatment, possibly blocking local competitors and paving the way for approval and commercialization.
References
[1] International Patent Classification (IPC) codes relevant to pharmaceutical formulations.
[2] Mexican Institute of Intellectual Property (IMPI). Patent database searches.
[3] US Patent and Trademark Office (USPTO) filings related to similar formulations.
[4] European Patent Office (EPO) patent family data.
[5] Clinical trial databases confirming therapeutic claims.
